Cybin Reports Strong Q2 2025 Results with Major Clinical Trial Progress in Neuropsychiatry Programs

Cybin Inc. has announced its second-quarter 2025 financial results alongside substantial progress in its neuropsychiatry development programs. The company reported strong institutional demand for its completed financing, which Interim CEO Eric So stated reinforces confidence in the company's scientific approach and therapeutic candidates as it moves toward key 2026 data readouts. The company's clinical development pipeline showed significant advancement across multiple programs during the quarter.

Cybin completed enrollment in its Phase 2 CYB004 study for generalized anxiety disorder, marking an important milestone in the development of this proprietary deuterated N, N-dimethyltryptamine molecule. The company also continued progressing CYB003 through both the Phase 3 APPROACH and EXTEND trials. CYB003, a proprietary deuterated psilocin analog, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for adjunctive treatment of major depressive disorder. Additional global regulatory approvals were secured to initiate the EMBRACE Phase 3 study for adjunctive MDD treatment, expanding the company's clinical development footprint.

The company's intellectual property portfolio grew substantially during the quarter, expanding to more than 100 granted patents and over 250 pending applications worldwide. This robust IP protection supports Cybin's position as a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare. The company is developing new and innovative next-generation treatment options to address the large unmet need for people suffering from mental health conditions. Additional information about the company's developments can be found at https://ibn.fm/CYBN.

Corporate governance developments included the Board forming a committee to conduct a CEO search to guide the next stage of growth and late-stage clinical development. Cybin maintains operations in Canada, the United States, the United Kingdom and Ireland. The company's research pipeline includes additional investigational compounds focused on 5-HT receptors, positioning Cybin to potentially introduce novel drugs that provide effective and durable results for patients suffering from mental health conditions. The full press release detailing these developments is available at https://ibn.fm/qQlOz.